

Laura Galli

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1459275/laura-galli-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

145
papers

2,626
citations

27
h-index

44
g-index

147
ext. papers

2,924
ext. citations

5
avg, IF

4.21
L-index

#	Paper	IF	Citations
145	Levels of Alpha-Fetoprotein and Association with Mortality in Hepatocellular Carcinoma of HIV-1-Infected Patients.. <i>Journal of Oncology</i> , 2022 , 2022, 3586064	4.5	1
144	Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV.. <i>PLoS ONE</i> , 2022 , 17, e0262917	3.7	0
143	Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection.. <i>PLoS ONE</i> , 2022 , 17, e0265348	3.7	0
142	Achieving virological control in pan-resistant HIV-1 infection: A case series.. <i>EBioMedicine</i> , 2022 , 77, 103908	3.8	1
141	Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV. <i>International Journal of Antimicrobial Agents</i> , 2021 , 59, 106492	14.3	1
140	Anti-HIV antibodies are representative of the latent reservoir but do not correlate with viral control in people with long-lasting virological suppression undergoing analytical treatment interruption (APACHE study). <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 1646-1648	5.1	1
139	Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen. <i>Aids</i> , 2021 , 35, 1513-1516	3.5	2
138	Changes in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) Index in Treated HIV-1 Infected People on Virological Suppression Who Switched to a Different Antiretroviral Regimen. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021 , 87, e169-e173	3.1	0
137	Benefits of a 12-week physical activity programme on muscle and bone health in people living with HIV. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021 ,	10.3	1
136	HIV-DNA undetectability during chronic HIV infection: frequency and predictive factors. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 2994-2997	5.1	0
135	The Role of Physical Activity for the Management of Sarcopenia in People Living with HIV. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	17
134	Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105893	14.3	11
133	Infections after Allogenic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1179-1188	4.7	14
132	A Mobile Application for Exercise Intervention in People Living with HIV. <i>Medicine and Science in Sports and Exercise</i> , 2020 , 52, 425-433	1.2	16
131	Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa456	1	5
130	A liquid chromatography-tandem mass spectrometry method for simultaneous determination of simeprevir, daclatasvir, sofosbuvir, and GS-331007 applied to a retrospective clinical pharmacological study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019 , 1120, 1-7	3.2	17
129	Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study). <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2039-2046	5.1	15

128	Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens. <i>Journal of Medical Virology</i> , 2019 , 91, 1937-1943	19.7	6
127	A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study. <i>Drug Design, Development and Therapy</i> , 2019 , 13, 477-479	4.4	2
126	Brief Report: Outcome of Acute Hepatitis B Virus Infection in HIV-1-Infected Patients: Possible Factors Associated With Resolution or Chronicity. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 82, 175-180	3.1	5
125	Brief Report: Association Between Low HIV-1 DNA and Western Blot Reactivity to HIV-1 Pol in Chronically Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 82, 373-376	3.1	2
124	Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy. <i>Aids</i> , 2019 , 33, 1256-1260	3.5	8
123	Viro-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression. <i>Aids</i> , 2019 , 33, 1987-1994	3.5	1
122	Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofy324	1	6
121	Immune activation, inflammation and HIV DNA after 96 weeks of ATV/r monotherapy: a MODAt substudy. <i>Antiviral Therapy</i> , 2018 , 23, 633-637	1.6	2
120	An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study. <i>Infectious Diseases</i> , 2018 , 50, 220-222	3.1	3
119	Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load. <i>PLoS ONE</i> , 2018 , 13, e0191300	3.7	3
118	Stepping up HIV-1 low-level viraemia surveillance in South Africa. <i>Lancet Infectious Diseases</i> , 2018 , 18, 130-131	25.5	2
117	Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018 , 79, 617-623	3.1	6
116	Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen. <i>International Journal of Antimicrobial Agents</i> , 2018 , 52, 492-499	14.3	9
115	Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients. <i>BMC Infectious Diseases</i> , 2017 , 17, 43	4	6
114	Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authorsResponse. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1549-1550	5.1	1
113	Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males. <i>PLoS ONE</i> , 2017 , 12, e0186367	3.7	12
112	Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. <i>PLoS ONE</i> , 2017 , 12, e0186549	3.7	18
111	The use of circulating cathodic antigen rapid test and serology for diagnosis of active <i>Schistosoma mansoni</i> infection in migrants in Italy, a non-endemic country: a cross sectional study. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2017 , 112, 452-455	2.6	6

110	A pilot study of brisk walking in sedentary combination antiretroviral treatment (cART)- treated patients: benefit on soluble and cell inflammatory markers. <i>BMC Infectious Diseases</i> , 2017 , 17, 61	4	27
109	Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 632-633	5.1	7
108	Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients. <i>BMC Infectious Diseases</i> , 2017 , 17, 723	4	3
107	Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients. <i>PLoS ONE</i> , 2017 , 12, e0182007	3.7	7
106	Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 812-815	5.1	6
105	Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir. <i>Medicine (United States)</i> , 2016 , 95, e3780	1.8	5
104	Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients. <i>Medicine (United States)</i> , 2016 , 95, e4144	1.8	5
103	High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects: Data from the ICONA Foundation Cohort. <i>Medicine (United States)</i> , 2016 , 95, e4434	1.8	2
102	Switch of predicted HIV-1 tropism in treated subjects and its association with disease progression. <i>Medicine (United States)</i> , 2016 , 95, e5222	1.8	4
101	Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1637-42	5.1	5
100	Immortal time bias: authorsReply. <i>Aids</i> , 2015 , 29, 860-1	3.5	1
99	Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy. <i>Journal of the International AIDS Society</i> , 2015 , 18, 20037	5.4	10
98	Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation: authorsReply. <i>Aids</i> , 2015 , 29, 857-9	3.5	
97	Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1436-9	5.1	4
96	Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfecting patients. <i>Brazilian Journal of Infectious Diseases</i> , 2014 , 18, 164-9	2.8	8
95	Optimal dietary calcium intake in HIV treated patients: no femoral osteoporosis but higher cardiovascular risk. <i>Clinical Nutrition</i> , 2014 , 33, 363-6	5.9	4
94	Immunological recovery after 24 weeks of antiretroviral therapy in patients with X4 virus during primary HIV infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 65, e27-9	3.1	3
93	Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19806	5.4	4

92	Predictors of lack of serological response to syphilis treatment in HIV-infected subjects. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19654	5.4	1
91	CD4 cell count and the risk of infective and non-infective serious non-AIDS events in HIV-positive persons seen for care in Italy. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19509	5.4	2
90	Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19811	5.4	1
89	Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy. <i>Aids</i> , 2014 , 28, 2407-15	3.5	15
88	Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 67, 258-67	3.1	2
87	Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results. <i>Aids</i> , 2014 , 28, 2269-79	3.5	19
86	Diagnostic value of IgG4 Indices in IgG4-related hypertrophic pachymeningitis. <i>Journal of Neuroimmunology</i> , 2014 , 266, 82-6	3.5	47
85	Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting. <i>Therapeutics and Clinical Risk Management</i> , 2014 , 10, 9-15	2.9	10
84	Identification of TRIM22 single nucleotide polymorphisms associated with loss of inhibition of HIV-1 transcription and advanced HIV-1 disease. <i>Aids</i> , 2013 , 27, 2335-44	3.5	14
83	Plasma fibroblast growth factor 23 and osteocalcin serum levels are associated with cardiovascular risk in HIV-1-infected patients receiving antiretroviral treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2960-3	5.1	4
82	Non-invasive fibrosis biomarkers - APRI and Forns - are associated with liver stiffness in HIV-monoinfected patients receiving antiretroviral drugs. <i>Liver International</i> , 2013 , 33, 1113-20	7.9	10
81	Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients: a matched cohort study. <i>Cancer</i> , 2013 , 119, 2710-9	6.4	2
80	Glucose tolerance in HIV-1 treated patients who switched from boosted-protease inhibitors to etravirine. <i>Aids</i> , 2013 , 27, 2661-3	3.5	
79	B-cell subset alterations and correlated factors in HIV-1 infection. <i>Aids</i> , 2013 , 27, 1209-17	3.5	56
78	Incidence, timing, and determinants of bacterial pneumonia among HIV-infected patients: data from the ICONA Foundation Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 63, 339-45	3.1	11
77	Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy. <i>European Journal of Epidemiology</i> , 2012 , 27, 657-65	12.1	56
76	Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies. <i>International Journal of Cancer</i> , 2012 , 130, 2990-6	7.5	24
75	Mortality of HIV-infected patients with or without cancer: comparison with the general population in Italy. <i>Antiviral Therapy</i> , 2012 , 17, 447-58	1.6	9

74	Immune recovery and T cell subset analysis during effective treatment with maraviroc. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 2474-8	5.1	9
73	Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 1224-7	5.1	14
72	Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 213-7	5.1	26
71	Monotherapy with atazanavir as a simplification strategy: results from an observational study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 60, e101-3	3.1	4
70	Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens. <i>Aids</i> , 2012 , 26, 1837-40	3.5	11
69	Visual outcome in ocular sarcoidosis: retrospective evaluation of risk factors. <i>European Journal of Ophthalmology</i> , 2011 , 21, 802-10	1.9	21
68	Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 56, e113-5	3.1	18
67	Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. <i>Aids</i> , 2011 , 25, 177-83	3.5	35
66	Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 56, e34-5	3.1	1
65	No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy. <i>Journal of Medical Virology</i> , 2011 , 83, 391-8	19.7	1
64	Integrase and fusion inhibitors transmitted drug resistance in naive patients with recent diagnosis of HIV-1 infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 56, e51-4	3.1	12
63	Perturbation of the natural killer cell compartment during primary human immunodeficiency virus 1 infection primarily involving the CD56 bright subset. <i>Immunology</i> , 2010 , 129, 220-33	7.8	20
62	Demographic and clinical features related to a symptomatic onset of Paget's disease of bone. <i>Journal of Rheumatology</i> , 2010 , 37, 155-60	4.1	11
61	Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trial. <i>Journal of Clinical Virology</i> , 2010 , 47, 253-74.5	7.4.5	4
60	Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. <i>Aids</i> , 2010 , 24, 924-8	3.5	38
59	Liver histology in HIV/hepatitis C-coinfected and HCV-monoinfected patients with persistently normal alanine aminotransferases. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 54, 107-8	3.1	11
58	Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy. <i>Antiviral Therapy</i> , 2010 , 15, 165-75	1.6	14
57	Survival of HIV-1 infected multidrug-resistant patients recycling enfuvirtide after a previous failure. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 51, 179-84	3.1	4

56	Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 50, 192-5	3.1	7
55	Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 51, 106-8	3.1	27
54	Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients. <i>Antiviral Therapy</i> , 2009 , 14, 339-347	1.6	18
53	Extraslesional detection and load of human papillomavirus DNA: a possible marker of preclinical tumor spread in cervical cancer. <i>Journal of Lower Genital Tract Disease</i> , 2008 , 12, 204-9	3.6	4
52	HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy. <i>Journal of Medical Virology</i> , 2008 , 80, 201-8	19.7	13
51	Does cyclosporin A affect CCR5 and CXCR4 expression in primary HIV-1-infected patients?. <i>Cytometry Part B - Clinical Cytometry</i> , 2007 , 72, 433-41	3.4	1
50	Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects. <i>European Journal of Endocrinology</i> , 2007 , 156, 503-9	6.5	33
49	Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 60, 831-6	5.1	15
48	Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir. <i>Aids</i> , 2007 , 21, 1648-51	3.5	16
47	Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity. <i>Aids</i> , 2007 , 21, 2366-7	3.5	0
46	Efficacy of valacyclovir vs acyclovir for the prevention of recurrent herpes simplex virus eye disease: a pilot study. <i>American Journal of Ophthalmology</i> , 2007 , 144, 547-51	4.9	66
45	Hepatitis C virus (HCV) coinfection in a cohort of HIV positive long-term non-progressors: possible protective effect of infecting HCV genotype on HIV disease progression. <i>Journal of Clinical Virology</i> , 2007 , 39, 82-6	14.5	12
44	Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir. <i>Journal of Medical Virology</i> , 2006 , 78, 1537-41	19.7	9
43	Comparison of an in-house and a commercial RD1-based ELISPOT-IFN-gamma assay for the diagnosis of Mycobacterium tuberculosis infection. <i>Clinical Medicine and Research</i> , 2006 , 4, 266-72	1.4	10
42	An in-house RD1-based enzyme-linked immunospot-gamma interferon assay instead of the tuberculin skin test for diagnosis of latent Mycobacterium tuberculosis infection. <i>Journal of Clinical Microbiology</i> , 2006 , 44, 1944-50	9.7	15
41	Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial. <i>Pancreatology</i> , 2006 , 6, 454-63	3.8	26
40	Phosphorylcholine coating may limit thrombin formation during high-risk cardiac surgery: a randomized controlled trial. <i>Annals of Thoracic Surgery</i> , 2006 , 81, 886-91	2.7	35
39	Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). <i>Aids</i> , 2006 , 20, 795-803	3.5	117

38	Liver fibrosis in HIV-positive patients with hepatitis C virus: role of persistently normal alanine aminotransferase levels. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 41, 63-7	3.1	34
37	The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 41, 447-52	3.1	7
36	Aprotinin and renal risk in cardiac surgery. <i>Transfusion</i> , 2006 , 46, 2207; author reply 2209-10	2.9	1
35	Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. <i>Lancet Oncology, The</i> , 2005 , 6, 369-76	21.7	219
34	Patients with known or suspected lung cancer: evaluation of clinical management changes due to 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) study. <i>Nuclear Medicine Communications</i> , 2005 , 26, 831-7	1.6	9
33	Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2005 , 56, 790-2	5.1	20
32	Determination of human papillomavirus (HPV) load and type in high-grade cervical lesions surgically resected from HIV-infected women during follow-up of HPV infection. <i>Clinical Infectious Diseases</i> , 2005 , 40, 451-7	11.6	25
31	Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine. <i>Journal of Psychopharmacology</i> , 2004 , 18, 355-65	4.6	31
30	Selected pool of peptides from ESAT-6 and CFP-10 proteins for detection of Mycobacterium tuberculosis infection. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 3469-74	9.7	36
29	Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy. <i>Journal of Medical Virology</i> , 2004 , 72, 181-6	19.7	7
28	Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome. <i>Aids</i> , 2004 , 18, 821-3	3.5	2
27	The NIQ of Lopinavir is Predictive of a 48-Week Virological Response in Highly Treatment-Experienced HIV-1-Infected Subjects Treated with a Lopinavir/Ritonavir-Containing Regimen. <i>Antiviral Therapy</i> , 2004 , 9, 537-543	1.6	10
26	Pretreatment of chronic active hepatitis C in patients coinfecting with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003 , 33, 146-52	3.1	35
25	5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study. <i>Psychopharmacology</i> , 2003 , 167, 72-8	4.7	75
24	Potential therapeutic role of para-aortic lymphadenectomy in node-positive endometrial cancer. <i>Gynecologic Oncology</i> , 2000 , 76, 348-56	4.9	202
23	A retrospective analysis of postradiation chemotherapy in 133 patients with glioblastoma multiforme. <i>Cancer Investigation</i> , 2000 , 18, 510-5	2.1	12
22	Meningeal carcinomatosis from transitional cell carcinoma of the bladder: report of two cases and review of the literature. <i>Cancer Investigation</i> , 1999 , 17, 402-7	2.1	9
21	Soluble E-selectin and intercellular adhesion molecule-1 plasma levels increase during acute myocardial infarction. <i>Journal of Cardiovascular Pharmacology</i> , 1997 , 30, 455-60	3.1	12

20	The Effect of Intracorporeal Injection Plus Genital and Audiovisual Sexual Stimulation Versus Second Injection on Penile Color Doppler Sonography Parameters. <i>Journal of Urology</i> , 1996 , 155, 536-540	2.5	43
19	Increased interleukin-10 serum levels in patients with solid tumours. <i>Cancer Letters</i> , 1996 , 104, 1-5	9.9	134
18	Double-blind stereo-EEG and FDG PET study in severe partial epilepsies: are the electric and metabolic findings related?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996 , 23, 1498-507		30
17	Prognostic effect of DNA content depends on the amount of the residual disease in ovarian tumours. <i>Journal of Obstetrics and Gynaecology</i> , 1996 , 16, 556-559	1.3	
16	Serum levels of soluble cell adhesion molecules (ICAM-1, VCAM-1, E-selectin) and of cytokine TNF-alpha increase during interleukin-2 therapy. <i>Clinical Immunology and Immunopathology</i> , 1995 , 76, 142-7		9
15	The Role of Intraoperative Therapy by Electron Beam and Combination of Adjuvant Chemotherapy and External Radiotherapy in Carcinoma of the Pancreas. <i>Tumori</i> , 1995 , 81, 23-31	1.7	28
14	Laser photocoagulation of choroidal neovascularization in pathologic myopia: long-term results. <i>International Ophthalmology</i> , 1994 , 18, 339-44	2.2	42
13	A comparison of transrectal hyperthermia, transurethral thermotherapy, urolume wallstent, and prostatic spiral for benign prostatic hyperplasia patients at poor operative risk. <i>Prostate</i> , 1994 , 24, 156-61	4.2	8
12	Evidence that apolipoprotein(a) phenotype is a risk factor for coronary artery disease in men <i>American Journal of Cardiology</i> , 1994 , 74, 346-51	3	30
11	Effect of yohimbine-trazodone on psychogenic impotence: a randomized, double-blind, placebo-controlled study. <i>Urology</i> , 1994 , 44, 732-6	1.6	69
10	Prostatic UroLume Wallstent for benign prostatic hyperplasia patients at poor operative risk: clinical, uroflowmetric and ultrasonographic patterns. <i>Journal of Urology</i> , 1993 , 150, 1641-6; discussion 1646-7	2.5	21
9	Is there an impact of birth weight and early life nutrition on bone mineral content in preterm born infants and children?. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1993 , 82, 711-3	3.1	41
8	Is there a role for transrectal microwave hyperthermia of the prostate in the treatment of abacterial prostatitis and prostatodynia?. <i>Prostate</i> , 1993 , 22, 139-46	4.2	35
7	Transrectal Prostatic Hyperthermia and Urinary Retention Secondary to Benign Prostatic Hyperplasia: A 2-Year Follow-Up Study. <i>Journal of Endourology</i> , 1992 , 6, 261-264	2.7	4
6	Transrectal microwave hyperthermia for benign prostatic hyperplasia: long-term clinical, pathological and ultrastructural patterns. <i>Journal of Urology</i> , 1992 , 148, 321-5	2.5	49
5	Transrectal microwave hyperthermia for advanced prostate cancer: long-term clinical results. <i>Journal of Urology</i> , 1992 , 148, 342-5	2.5	30
4	Transrectal hyperthermia-induced histological and ultrastructural changes of human benign prostatic hyperplasia tissue. <i>European Urology</i> , 1992 , 22, 74-8	10.2	6
3	Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. Phenotypic and functional analysis of the peripheral blood mononuclear cells. <i>Cancer Immunology, Immunotherapy</i> , 1990 , 32, 161-6	7.4	14

2	Morphodynamic and biochemical assessment of seminal plasma in patients who underwent local prostatic hyperthermia. <i>Prostate</i> , 1990 , 16, 325-30	4.2	15
1	Local bacillus Calmette-Guerin therapy for superficial bladder cancer: clinical, histological and ultrastructural patterns. <i>Scandinavian Journal of Urology and Nephrology</i> , 1990 , 24, 191-8		6